ARTICLE | Company News
Cerep, Laboratoires Thea deal
January 12, 2009 8:00 AM UTC
Laboratoires Thea received an exclusive, worldwide license to develop and commercialize Cerep's LFA-1 (CD11a-CD18) antagonist to treat ophthalmic disorders. Cerep will receive an undisclosed upfront ...